迈博药业-B(02181.HK)：委任钱卫珠为提名委员会成员
MabpharmMabpharm(HK:02181) Ge Long Hui·2025-10-31 11:08

Group 1 - The company announced changes in its nomination committee effective from October 31, 2025 [1] - Executive Director Qian Weizhu has been appointed as a member of the nomination committee [1] - Executive Director Tao Jing will no longer serve as a member of the nomination committee [1] - Zhang Yanyun, an independent non-executive director and chairman of the remuneration committee, has been designated as the Chief Independent Non-Executive Director [1]